NuVasive brings porous titanium spine implants to its TLIF offerings

Spine
(Pixabay)

With the launch of its latest spine implant, NuVasive has expanded its porous titanium portfolio to all transforaminal lumbar interbody fusion surgeries, or TLIF procedures.

The new Modulus TLIF-A implant features a design specific for anterior implant positioning and anterior column support. It joins the TLIF-O interbody device line the company launched in June, which feature a lordosis cut in the oblique plane, which makes it easier to align the spine without introducing deformities that affect side-to-side movements.

Both are designed to be inserted and rotated using the same instrument, using the company’s MAS TLIF and MAS Midline access systems, and feature a 3D-printed titanium lattice. That structure mimics the stiffness of bone while providing radiolucency and better visualization compared to solid titanium implants. 

RELATED: NuVasive launches all-in-one spine surgery suite

Meanwhile, the gaps in the implants’ porous endplates allow for new bone in-growth and on-growth, helping to secure it in place between the vertebrae. These additions increase the company’s footprint among interbody fusion devices, part of what it estimates as a $1.2 billion market.

“NuVasive’s implants are designed to combine the inherent benefits of porosity with the advantageous material properties of PEEK and titanium to create implants intelligently designed for fusion, which we believe outperforms traditional and competitive implants in the market,” President Matt Link said in a statement. 

With the Modulus TLIF-A implant, NuVasive plans to launch its full Advanced Materials Science TLIF portfolio in the global market later this year.

Suggested Articles

Researchers at the University of Maryland are developing an experimental diagnostic for COVID-19 that could provide a visual result in 10 minutes.

The FDA approved its first radioactive diagnostic dye designed to map out the characteristic tau protein tangles found in brains with Alzheimer's.

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.